Low efficiency, significant toxicity, polymer polydispersity and poorly understood delivery mechanisms have initially plagued the field of polymer-based gene therapy. Numerous strategies have helped to improve polyplexes, including the development of biodegradable polymers with reduced toxicity, incorporation of cell targeting, surface shielding and additional transport domains for effective and specific delivery, or improved chemistry for syntheses of polymers with uniform size and topology. Combined biooptical imaging and bioinformatics, providing insights into transfer bottlenecks, have helped to design improved polyplexes. Bioresponsive multifunctional polymers adapt in a dynamic manner to delivery barriers for efficient transfer of pDNA or siRNA to the target site.
Experimental and computational analysis of entry barriers has shed light on the intracellular delivery mechanisms and kinetics of polyplexes
In comparison to viral vectors, synthetic vector formulations are far less effective in transfection. This stems from numerous extracellular and intracellular barriers entrapping or destroying a majority of the nucleic acids before they reach the site of action. The barriers encountered by the synthetic vectors include nontarget cells, extracellular fluids and extracellular matrix (ECM), 1 cell entry, endolysosomal escape, 2,3 cytoplasmic trafficking, vector unpacking 4, 5 and, in the case of plasmid DNA (pDNA)-encoded gene transfer, nuclear localization. 6 In the past, assessment of different nonviral formulations such as polymer-based pDNA complexes (polyplexes) has been largely based on transfections measuring marker gene expression levels as readout. Such black-box strategies provide only indirect information, for example, by comparison of nanoparticles with or without a specific transport function (such as a targeting ligand, shielding
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Prospects
Improved monitoring on single nanoparticle and cell level with high temporal and spatial resolution will unravel delivery mechanisms and bottlenecks Validated data on transfection kinetics and intracellular distribution in combination with stochastic simulations will help to predict the optimal design of polyplexes In vivo imaging methods using living animals will be very helpful for optimizing delivery Dynamic, bioresponsive polymers will cope better with the multiple sequential delivery steps Improved chemistry will provide monodisperse polymer structures with defined size, topology and transport domains Better defined and improved pDNA, RNA, siRNA polyplexes will fuel clinical development pipelines molecule or endosomal escape domain). However, no direct information on the involved pathways and critical bottlenecks of the transfection process has been obtained. To predict, the optimal design of polyplexes remains a major challenge in synthetic gene delivery.
Recent investigations have started to evaluate the pharmacokinetics of polyplexes at the cellular level in more detail and compare them with theoretical mathematical models. For example, the transport of different polyethylenimine (PEI) polyplexes into cellular compartments was compared in cell culture, using cellular fractionation and real-time quantitative PCR. 7, 8 In parallel, multicompartment mathematical models were applied to time series measurements of cellular trafficking. 7, 9 Such computational methodology, when complemented with validated experimental data, provides a quantitative means for presenting the spatiotemporal dynamics of intracellular interactions between gene carriers and cellular components at a nanoscale level. First assessments, using PEI-based carriers as examples, predict that approximately only 1% of the internalized DNA is delivered to the nucleus. 9 Endosomal escape was identified as a significant rate-limiting parameter;
7 cell entry appears, at least in vitro, to have a smaller impact on the efficiency. 8 Dinh et al. 9 point out that the almost two-dimensional cell morphology under cell culturing conditions, in contrast to the complex, three-dimensional in vivo situation, may have a larger impact on the efficacy of gene delivery systems than previously assumed.
Computational analysis is critically dependent on a valid database derived from accurate experimental cell biology data. In this respect, improved imaging technologies are available for visualization and quantitation of cell uptake of polyplexes with high temporal and spatial resolution. For example, single particle tracking is capable of monitoring the surprisingly fast kinetics of receptor-mediated uptake and trafficking in living cells, demonstrating uptake, intracellular trafficking and first perinuclear location of targeted polyplexes within 5 min of transfection (Figure 1) . 10 Genetically, marking the cytoskeleton (for example, actin or tubulin) or other intracellular structural proteins (for example, RAB proteins) with a fluorescent protein (for example, GFP) enables monitoring of intracellular transfection pathways in real time. Interestingly, the internalization route resulting in successful gene expression may depend both on the polyplex type and the selected cell line. 11, 12 While clathrin-and/or lipid-raft dependent internalization was observed for medium size (50-200 nm) nanoparticles, o25 nm small nanoparticles were found to be taken up by a distinct, nondegradative pathway, and large particles by further pathways including macropinocytosis. Using very elegant QD (quantum dot)-FRET (fluorescence resonance energy transfer) technology, Leong and colleagues 5 analyzed uptake and intracellular unpackaging of polyplexes in a quantitative manner. By comparison of intracellular kinetics and dissociation of three different polyplex types (formed with QD-labeled pDNA and Cy5 labeled PEI, chitosan or polyphosphoramidates) they conclude that for efficient gene transfer, sufficient polyplex stability to avoid DNA degradation or fast endosomal escape is required, while at the same time, the rapid release of DNA after reaching the nucleus is essential-a challenging task, which will be discussed in a subsequent section of this review. The QD-FRET analysis demonstrates the presence of intact polyplexes in the nucleus, but also free DNA in the cytosol. Cytosolic dissociation is presumably facilitated by the presence of negatively charged proteins and RNA. 
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Nuclear delivery of PEI polyplexes is strongly influenced by the temporary breakdown of the nuclear membrane during cell division, but can happen also in nonproliferating cells. 6 Regrettably, in vitro cell culture has only very limited predictive value for in vivo gene transfer. More sophisticated systems, such as three-dimensional spheroid culture, are better models for the morphological and functional features of in vivo tumors (for example, cell-cell, ECM-cell contacts). They allow long-term kinetic studies of gene expression and reveal additional polyplex characteristics like tumor tissue penetration capabilities and changes in cytotoxicity compared to two-dimensional cell cultures, which are relevant for in vivo application.
14 Analysis in mice showed that serum proteins and the extracellular matrix are surprisingly effective in negatively affecting and dissociating carriers, severely compromising delivery efficacy in particular when polyplexes are injected intravenously. 1 Such mechanistic analyses are of key importance, because they point out important directions for refining polyplexes, for example, by bioreversible covalent stabilization. The latter method, as described by Neu et al. 15 and other investigators in previous work, applies bioresponsive crosslinkers to chemically stabilize the carrierpayload ionic complex and thereby reduces premature unpacking in the circulation.
Biodegradable polymers have the potential to overcome the cytotoxicity problem of first-generation carriers PEI has been considered as the gold standard in many in vitro and in vivo applications in terms of transfection efficiency, based on favorable characteristics of DNA protection, cell binding and uptake, endosomal escape and release from the carrier. A drawback of such a jackof-all-trades is the significant cytotoxicity of PEI both in vivo and in vitro, at least for the high-molecular weight forms of the polymer. 16, 17 Also the limited degradability of PEI presumably excludes repeated systemic therapeutic use, restricting it to a few localized applications. Numerous reports describe analogous biodegradable polymers, which decompose to smaller metabolites of lowered toxicity. Of the various available hydrolyzable structures, poly(amino esters; PAE) have received much attention due to their favorable degradation profile (half-lives in the order of days), delivery efficiency and easy synthesis. 18 Different diacrylates were reacted with various primary amines or oligoamines. [19] [20] [21] [22] Using PAEs, effective in vitro DNA transfer into various cell types was demonstrated with favorable efficacy/cytotoxicity profiles in comparison to PEI. Defined linear structures, 19 random structures 20, 21 or branched pseudodendrimer structures 22 were generated, with amine and linker-dependent properties, including for example, promising in vivo gene delivery into tumors upon systemic application in mice. 22 The different redox potential between the oxidizing extracellular and reducing intracellular environment has been exploited for polymer biodegradation. 17, [23] [24] [25] [26] Disulfide bonds are stable in the circulation, but are cleaved upon entry into the reductive intracellular environment, thus allowing site specific degradation.
Linear poly(ethylenimine sulfide), a biodegradable analog to linear PEI, was synthesized and displayed high efficiency but reduced cytotoxicity. 23 Intracellular degradation was demonstrated using fluorescence quenching of conjugated BODIPY-dye. Similarly, disulfide cross-linked low-molecular weight linear PEI displayed outstandingly high transfection efficacy. 17 Manickam and Oupicky 24 used disulfide-based copolymerization of a histidine-rich peptide and an SV40-derived nuclear localization sequence peptide. Transfection activity was enhanced by the increasing content of the histidine-rich peptide, while no clearly measurable effect of the nuclear localization sequence was found.
Combinatorial chemistry allows rapid polymer development for gene delivery
Polymer design for gene delivery suffers from vast combinations of potential variables and the complex biological environment in which the carriers are employed. Furthermore, recent studies emphasize the need for specialized systems, as not every carrier is appropriate for every task and there is an increasing need for adaptive polymers, which can deal with changing biochemical environments. 1, 27 Combinatorial chemistry can drastically shorten the development cycles by producing a large set of system descriptors (chemical structures, physical properties and biological characteristics associated with these structures), which can be used rationally to design vector systems. The concept of high-throughput combinatorial chemistry was previously introduced to the gene therapy field by the Langer lab, synthesizing a library of 2350 single entity PAEs. The information derived from this library was subsequently used in several applications, for example, by Green et al. 19 to construct optimized PAEs for human endothelial cell transfections in high serum conditions. Starting with low-molecular weight 0.42 and 1.8 kDa PEI and 24 bi-and oligoacrylate esters, Thomas et al. 21 developed a 144-member library. In vitro and in vivo screening identified nine effective polymers, of which two showed systemic in vivo gene delivery to the lung with reduced toxicity compared to PEI. To take full advantage of the potential of such encouraging combinatorial approaches, further optimization of polymer chemistry and purification, resulting in libraries of monodisperse polymers with defined size and topology, better models to correlate in vitro and in vivo efficacy, as well as computational assistance for elucidating structure-activity relations will be necessary. One has to emphasize that any high-throughput screening, which is only dependent on standard in vitro test systems would not necessarily select candidate vectors with the highest in vivo efficacy.
Sequence-defined polymers allow detailed structure-activity relationship studies For better defined copolymer structures and libraries with defined molecular weight and topology, [21] [22] [23] 28 meaningful structure-transfection correlations are Gene therapy progress and prospects D Schaffert and E Wagner possible. However, more detailed studies are not possible, even with such systems, due to the limited design space and/or their polydispersity. This limitation may be circumvented by alternative chemistry methodologies, including, for example, dendrimer synthesis and/or solid-phase synthesis, which provide defined monodisperse products by the control of position and structure of every unit in a polymer (see Figure 2) . Hartmann et al. 29, 30 adopted standard Fmoc (fluorenylmethoxy-carbonyl) protective group-based peptide solid-phase chemistry to build up a small library of monodisperse, sequence-defined poly(amidoamine) polymers. Defined incorporation of polyethylene glycol (PEG) or oligopeptide blocks was possible. Different PEG-poly(amidoamine) copolymers were synthesized, where the cationic nature of the poly(amidoamine) segments was systematically varied. This modulated the structure of the resulting polyplexes, ranging from extended ring-like structures to highly compact toroidal structures. Importantly, stable single-polynucleotide complexes could be generated, as described similarly for sequence-defined synthetic peptidebased block copolymers by DeRouchey et al. 31 or previous published work for synthetic polylysine-PEG conjugates.
Polymer optimization for siRNA delivery in vitro and in vivo is ongoing Small interfering RNA duplexes (siRNA), which upon delivery into the cytoplasm can induce specific posttranscriptional gene silencing, mediated by the RNAinduced silencing complex, have entered the biomedical field with amazing speed. At least five siRNA drugs (in free, unmodified or chemically modified form) have already entered clinical testing. 32 The development of optimized in vivo delivery systems for siRNA presents an interesting challenge (as reviewed in de Fougerolles 32 Aigner 33 Meyer and Wagner 34 and Aagaard Rossi ). The existing experience from pDNA and antisense oligonucleotide delivery boosted rapid development of polymeric carriers for siRNA delivery. The synthetic nature of siRNA opened new options, such as stabilizing modifications and covalent conjugation to carrier molecules. 36 Also, the different requirements and polyplex characteristics have become evident, with the smaller size of siRNA and the aim to deliver and release into the cytosol as opposed to the required nuclear delivery of pDNA. For example, some PEI formulations that effectively work for pDNA delivery show only moderate siRNA delivery capacity. Behr and colleagues 37 showed that Gene therapy progress and prospects D Schaffert and E Wagner making siRNAs 'gene-like,' by incorporating short complementary sticky overhangs, increased PEI polyplex stability and gene silencing up to 10-fold. Alternatively, novel polymers, 25, 38 or modifications of existing polymers, 3, 39, 40 have been generated with improved siRNA transfer potential. Building on and extending previous related studies, Wang et al. 27 have reported a small solid-phase synthesis derived library of reversibly polymerizable surfactants for siRNA delivery, which consist of a lipophilic anchor, a cationic siRNA complexing region and free thiols, encaging the payload into nanoparticles by thiol-mediated template polymerization. The solid-phase synthesis allowed easy refinement of the molecules and the sulfhydryl surface can be used for various modifications. The transfection efficacy of the surfactant complexes is comparable to cationic lipids, but provides a better serum stability under in vitro conditions.
Biopolymers including atelocollagen and chitosan have been successfully introduced for in vivo siRNA delivery. Chitosan is able to form stable complexes with siRNA and can successfully induce target knockdown in cells. 41 The mucoadhesive properties of chitosan were exploited for intranasal delivery of siRNA resulting in an effective knockdown of enhanced green fluorescent protein (EGFP) in bronchiolar epithelial cells of EGFP transgenic mice with no apparent toxicity. 42 Systemic delivery of siRNA chitosan polyplexes was also effective, as shown in a breast cancer xenograft model in mice. 43 Transferrin-receptor targeted, PEG-shielded siRNA polyplexes based on cyclodextrin-polycation conjugates were developed by Davis and colleagues 44 for intravenous delivery and therapy of subcutaneous tumors. Recently, this group correlated the functional efficacy of polyplexes with biodistribution data using multimodal in vivo imaging in mice. 45 Although PET imaging demonstrated similar tumor localization for both nontargeted and transferrin-targeted siRNA nanoparticles, the latter showed higher functional activity in tumors as monitored by in vivo luciferase imaging. This is consistent with the notion that receptor-mediated cellular uptake into tumor cells by the transferrin receptor is essential for effective siRNA delivery. 45 Other examples of siRNA polyplexes for receptor-targeted in vivo delivery were recently reported, such as hepatocyte targeting utilizing the asialoglycoprotein receptor, 36 or brain targeting with a rabies virus-derived peptide ligand for the acetyl-choline receptor. 46 Multifunctional polymers can be designed with defined topology and dynamic transport domains
Since the first demonstration of receptor-mediated delivery of polyplexes by George and Catherine Wu 20 years ago, numerous polyplex targeting strategies have been developed, which go far beyond the scope of the current review. Recent concepts include peptide-based targeting ligands, and new strategies for simultaneous and defined incorporation of targeting and shielding functions into polyplexes. 44, [47] [48] [49] For example, the cyclic pentapeptide CNGRC conjugated with PEG, and attached to PEI through noncovalent phenyldiboronic acid/salicylhydroxamic acid bridges, was used for polyplex formation targeting CD13 of tumor and tumor endothelial cells. Intravenous application of such polyplexes delivering p53-encoding pDNA in tumor-bearing mice showed encouraging therapeutic antitumoral effects. 47 A 7-mer peptide (MQLPLAT) targeting the fibroblast growth factor 2 receptor was incorporated into PEGylated PEI polyplexes. 48 Two approaches were compared, conjugating the peptide to PEI through a PEG spacer either before (premodified) or after (postmodified) complexation of PEI with DNA. Both approaches led to similar biophysical properties, but only the postmodification approach resulted in increased cell uptake and transfection, presumably because of better accessibility of the peptide ligand to the fibroblast growth factor receptor.
Recent carriers incorporate several transport functions into one single polymeric carrier in a modular fashion. For cytosolic delivery of tumoricidal double-stranded poly-IC RNA, a tetraconjugate was constructed containing EGF as a targeting molecule, PEG for shielding, PEI for payload compaction and the lytic peptide melittin. 50 The next logical step is the design of polymeric carriers with defined size, topology and defined attachment sites for the functional domains. Wood et al. 49 developed a three component system based on a lineardendritic hybrid polymer. By the use of well-defined components, PAMAM-SH dendrimer G4, heterobifunctional PEG, a peptide (WIFPWIQL) targeting glucose-regulated protein-78 kDa (GRP78) and orthogonal coupling chemistry, the site-specific conjugation was possible, yielding a monodisperse product. A physical separation of the different domains was achieved by the structure of the polymer, thus avoiding steric interaction of the domains. The modular conjugate transfected GRP78-positive prostate cancer cells at levels almost 10-fold higher than an optimized formulation of branched PEI.
For efficient nucleic acid delivery, polymeric carriers have to cope with apparently contradictory demands: to stabilize the nucleic acid against degradation, but release it at its biological site of action; to shield the polyplex during circulation in the blood stream, but to deshield it upon cell entry; and to leave the cell membranes intact, but to rapidly destabilize the endosomal membrane. Nature has developed its own type of nanoparticles to resolve such a paradox: viruses, which sense their microenvironment and undergo dynamic structural changes, which support their infection process. Researchers have started to design synthetic nanoparticles with virus-like behavior. 51 These polyplexes contain chemical units programmed to respond to the subtle difference between the various extra-and intracellular compartments, including, for example, pH, reducing environment or enzymes. Stimuli-responsive polyplexes [52] [53] [54] react with structural alterations such as conformational changes, cleavage of chemical bonds, exposure of functional domains or disassembly (see Figure 3 ). In addition to physiological differences, programmed nanosystems may also be responsive to artificial stimuli as applied in physical targeting strategies including magnetic fields, 55 or light. 2, 56 For example, PEG-shielded polyplexes that in the endosomal acidic environment release their PEG shield by cleavage of pHGene therapy progress and prospects D Schaffert and E Wagner labile bonds displayed improved transfection efficiency. 57 pH-responsive polyplexes were also developed for siRNA delivery. 3, 36 An elegant strategy was developed for hepatocyte-targeted in vivo siRNA delivery by Rozema et al. 36 A membrane-destabilizing poly(vinyl ether) polymer was covalently conjugated with siRNA through a disulfide bond and reversibly masked by pH-labile ligation of PEG as shielding domain and N-acetylgalactosamine as targeting ligand. The applied linkers are either cleaved at acidic pH in endosomes or the reductive intracellular environment. The resulting polyconjugate had a size of approximately 12 nm. Specific hepatocyte targeting and knockdown of apoB and ppara target mRNA was demonstrated.
Prospects
Biomaterial sciences have already demonstrated that polymers can be designed in a very biocompatible, nontoxic and nonimmunogenic form, which in theory enables repeated administrations and long-lasting therapeutic effects. Despite significant maturation of polymer-based gene vectors over the last 20 years, the roadmap for developing clinically used polymeric carrier is still filled with significant obstacles and challenges. However, improved monitoring of polyplex prototypes at the single cell and single nanoparticle level, with high temporal and spatial resolution, will unravel intracellular delivery mechanisms and bottlenecks. Data on transfection kinetics and intracellular distribution in combination with stochastic simulations will help to predict the optimal design of polyplexes. To reach this goal, the models predicting intra-and extracellular barriers have to be better defined and fed with validated, standardized experimental data to allow a correct prediction of biodistribution and kinetics of delivery. In vivo multimodal imaging methods in experimental animals and human subjects will be very helpful for optimizing the in vivo delivery demands. Dynamic, bioresponsive polymers will better cope with the multiple sequential delivery steps. Notably, improved chemistry will provide monodisperse polymer structures with defined size, topology and transport domains. In combination with computer-assisted combinatorial synthesis, this will be essential for better elucidation of structure-activity relationships. Defined structures will also be essential for the GMP production of clinical grade materials. The first polymeric gene carriers, including PEI and polylysine derivatives, have already been tested in clinical trials, focusing on local administration to tumors (PEI in bladder carcinoma), or regional delivery to airway epithelium (PEG-polylysine in cystic fibrosis), and additional clinical cancer therapies with pDNA or siRNA polyplexes are expected to start this year. The design of the therapeutic nucleic acid vector component (pDNA, DNA minicircles and modified siRNA) is an additional rapidly developing field not covered in this review. It is already clear that the pharmacological profile (stability, immunogenicity, 58 tissue specificity and persistence) of the nucleic acid can be tailored for a given indication and administration modality (local, systemic, single or repeated dosage). Together with polymer development, this will contribute to the design of pDNA, RNA, siRNA polyplexes, which will fuel clinical development pipelines in the near future. Figure 3 Transfection process using a biodegradable, bioresponsive polymeric system. After docking to the cell by ligand-receptor interaction, the vector is internalized into an endosomal vesicle. This can be actively transported to the perinuclear region by microtubules. The acidic pH shift in the maturating endosome unmasks a domain which disrupts the endosomal membrane. The particle is released into the cytoplasm. Vector unpacking by degradation of the polymeric backbone (disulfide, ester bonds) may occur in a time-and environment-dependent fashion either in the cytosol or in the nucleus. Dependent on the form of nucleic acid, the payload is processed in the cytosol (siRNA) or has to enter the nucleus (pDNA). pDNA, plasmid DNA; siRNA, small interfering RNA.
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